Intraocular therapy in noninfectious uveitis

Rocco Luigi Modugno; Ilaria Testi; Carlos Pavesio

doi:10.1186/s12348-021-00267-x

Intraocular therapy in noninfectious uveitis

J Ophthalmic Inflamm Infect. 2021 Oct 10;11(1):37. doi: 10.1186/s12348-021-00267-x.

Authors

Rocco Luigi Modugno¹, Ilaria Testi², Carlos Pavesio^{3

4}

Affiliations

¹ Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy.
² Moorfields Eye Hospital, National Health Service Foundation Trust, 162 City Rd, Old Street, London, EC1V 2PD, UK.
³ Moorfields Eye Hospital, National Health Service Foundation Trust, 162 City Rd, Old Street, London, EC1V 2PD, UK. c.pavesio@nhs.net.
⁴ Biomedical Research Centre, Institute of Ophthalmology, UCL, London, UK. c.pavesio@nhs.net.

Abstract

Systemic corticosteroids and immunosuppressant agents are the mainstay of therapy for non-infectious uveitis (NIU). However, the risks associated with systemic administration and the need of delivering an effective and safe anti-inflammatory treatment targeted to the site of inflammation have prompt the use of local therapy in the management of NIU. This review will analyse the different local treatment options available, including corticosteroids, anti-vascular endothelial growth factor (VEGF), methotrexate and the recent biologics.

Keywords: Anti-tumor necrosis factor (TNF) α; Anti-vascular endothelial growth factor (VEGF); Biologics; Corticosteroids; Immunosuppressive agents; Intravitreal; Local therapy; Methotrexate; Non-infectious uveitis.

Publication types

Review